Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LVIVO-TaVec400 in Relapsed/Refractory Multiple Myeloma
NCT07399444Phase 1Not yet recruiting
- Sponsor
- Institute of Hematology and Blood Diseases Hospital
- Start
- Jan 2026
- Primary completion
- Jul 2028
- Modality
- Gene Editing, Gene Silencing, CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of LVIVO-TaVec400 in multiple myeloma (MM), sponsored by Institute of Hematology and Blood Diseases Hospital. Primary endpoints: Dose-Limiting Toxicity at 2 years, Treatment-Emergent Adverse Events at 2 years and 3 more. Planned start Jan 2026; status: not yet recruiting.
02
Drugs
LVIVO-TaVec400
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT07399444.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07399444.